A Study to Evaluate the Effect of Maridebart Cafraglutide on Insulin Sensitivity and β-cell Function in Participants With Type 2 Diabetes Mellitus

This study tests whether maridebart cafraglutide — a new medication that combines GLP-1 and GIP hormone activity (similar to drugs like tirzepatide) — can improve insulin sensitivity and the functioning of insulin-producing cells (beta cells) in people with Type 2 diabetes. **You may be eligible if...** - You are between 18 and 70 years old - You have a BMI between 27 and 45 kg/m² - You have had Type 2 diabetes for at least 6 months - You are managing your diabetes with diet, exercise, and a stable dose of metformin (with or without one other diabetes medication) **You may NOT be eligible if...** - You have Type 1 diabetes or a history of diabetic ketoacidosis - You have had a severe hypoglycemic episode (requiring someone else's help) in the past 6 months - You have diabetic eye disease requiring urgent treatment - You have a history of pancreatitis or thyroid cancer Talk to your doctor to see if this trial is right for you.